Company intelligence / Profile preview

Arpida Ltd

Reinach/Munchenstein (near Basel), Switzerland6sense.com ↗

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

Arpida's lead product iclaprim completed Phase III trials for complicated skin and skin structure infections, but received a negative recommendation from the FDA advisory board in November 2008. The company was pursuing European marketing authorization as of 2009.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculesantibioticsantifungals
Industry: Biotech

Partnerships

F. Hoffmann-La Roche Ltd (royalty position in one lead compound)[2]

Beyond the preview

Go deeper on Arpida Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arpida Ltd.

Explore the full profile